Abstract
We report a case of a woman in her 50s with chronic teprotumumab-associated sensorineural hearing loss. The patient presented with chronic thyroid eye disease with proptosis and diplopia despite systemic thyroid control and orbital decompression. She was started on teprotumumab but developed tinnitus after the third dose, followed by frank hearing loss after the fifth dose. Her audiogram showed bilateral mild to moderate-severe hearing loss, which was significantly worse compared with her baseline audiogram obtained prior to treatment. Teprotumumab was immediately stopped, however repeat audiogram 6 weeks later showed no improvement. Given potentially irreversible sensorineural hearing loss, we recommend close monitoring with regular audiometric testing before, during and after teprotumumab therapy and propose potential treatment to reverse its effects in the ear.
Reference39 articles.
1. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials;Kahaly;Lancet Diabetes Endocrinol,2021
3. Teprotumumab for thyroid-associated ophthalmopathy;Smith;N Engl J Med,2017
4. Teprotumumab for the Treatment of Active Thyroid Eye Disease
5. Amarikwa L , Sears CM , Clauss K . Teprotumumab-Related adverse events in thyroid eye disease. Poster presented at: the American Society of ophthalmic plastic and reconstructive surgery 52nd annual fall scientific symposium; November 11-12, 2021; New Orleans, Louisiana, United States.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献